Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Syndax Pharmaceuticals Inc (SNDX)

Syndax Q3 revenue rises 82% to $83.3 million; net loss narrows to $49.4 million

Positive Impact 4 of 5 earnings Written later

Syndax reported third-quarter 2026 total revenue of $83.3 million, up from $45.9 million a year earlier, and a net loss of $49.4 million, or $0.55 per share, versus $60.7 million, or $0.70 per share, in the prior-year quarter. The company also said its Chief Financial Officer, Keith Goldan, will retire effective November 9, 2026, and Aaron A. Ondrey will succeed him on the same date.

Key points

  • Revuforj net revenue was $60.7 million in Q3 2026, up 90% year over year; Niktimvo collaboration revenue to Syndax was $22.6 million.
  • Q3 2026 research and development expenses rose to $67.5 million from $56.3 million; SG&A fell to $43.7 million from $44.9 million.
  • Company continues to expect 2026 R&D plus SG&A expenses of about $400 million, excluding about $50 million of estimated non-cash stock compensation.
  • Ondrey joins as CFO effective November 9, 2026, with a $543,000 base salary and a 45% target bonus; Goldan will continue as an advisor for an interim period.

The filing

CompanySyndax Pharmaceuticals Inc (SNDX)
Form8-K, current report
Filed with the SECNov 2, 2026, 4:02 PM ET
Accession number0001193125-26-443613

Items reported: 2.02 Results of Operations5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.